Radionuclide therapy

Fisher, D. R. Assessments for high dose radionuclide therapy treatment planning. Radiat. Prot. Dosimetry 105(1—4) 581—586. 2003. 

De Jong M et al (1998) Internalization of radiolabelled [DTPA(0)]octreotide and [DOTA(O), Tyr(3)]octreotide Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Com 19 283-288... 

The developments in radionuclide therapy with radio labeled antibodies and bone-seeking radiopharmaceuticals have been extensive. This necessitates more accuracy in radiation absorbed dose estimates. Many radionuclides attached to various targeting agents have been studied. Some rare earth radionuclides used in internal emitter therapy are listed below. 

Panigone S, Nunn AD. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs a novel approach to radionuclide therapy. Quart. J. Nucl. Med. Mol. Imaging 2006 50 310-321. 

In the radiotherapy of tumours overexpressing somatostatin receptors (a method known as peptide receptor radionuclide therapy (PRRT)), is the most widely used radionuclide [1.13], Recently, Lu 497 keV E 208... 

KWEKKEBOOM, D.J., et al., Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs, J. Nucl. Med. 46 (2005) 62S-66S. 

Peptide receptor radionuclide therapy (PRRT) and peptide receptor imaging of malignant neoplasms have become a primary focus of interest in nuclear medicine. Neuroendocrine tumours frequently overexpress... 

DE JONG, M., et al., [ Lu-DOTA ,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy, Int. J. Cancer 92 (2001) 628-633. 

TABLE 7.3. INSULIN LEVELS IN AN INSULINOMA BEARING DOG BEFORE AND AFTER RADIONUCLIDE THERAPY WITH Y-DOTATOC... 

The extreme clinical importance of targeted radionuclide therapy with these analogues necessitates their application as early a possible in cancer patients. Cost effective, on-site preparation of matched pairs of diagnostic and therapeutic radiopharmaceuticals clearly is the way for the future. 

Lu-DOTATATE FOR POTENTIAL APPLICATION IN PEPTIDE RECEPTOR RADIONUCLIDE THERAPY... 

One of the most promising analogues for peptide receptor radionuclide therapy (PRRT) is the DOTA conjugated octreotate peptide ([DOTA(0),Tyr(3)-Thr(8)]octreotate), which has a higher affinity for somatostatin receptors than does octreotide [11.3,11.4] and can be easily labelled with... 

For the past two decades, there has been considerable interest in the use of short lived, moderate energy, beta emitting radionuclides for targeted radionuclide therapy [12.1-12.3]. This therapy involves the use of a radiolabelled molecule to selectively dehver a cytotoxic level of radiation to a diseased site with maximum radiation dose to the tumour and minimum radiation dose to normal organs. A number of beta particle emitting radionuchdes such as Lu, Sm and Ho are available for targeted radionuchde therapy for a wide range of tissues. The physical characteristics of these radionuchdes are listed in Table 12.1. 

---